An Emerging Biotech Customer Base Helps Drug Delivery Firms Balance Risks
Executive Summary
When Inhale Therapeutic Systems bought Shearwater, a provider of PEG (polyethylene glycol) technology and development services, it did so to extend its drug delivery capabilities beyond particle-based formulations. But another part of the rationale was to jigger its mix of programs to include both near- and longer-term projects, and to achieve a balance of high- and low-risk projects. As evidenced by its recent spate of deal announcements, the emerging deal-making power of small and mid-sized companies is helping Inhale accomplish those goals.
You may also be interested in...
OTC Loperamide Cardiovascular Label Warnings In US Spread To Perrigo Products
FDA approval for Perrigo's ANDA for two loperamide products listed as tablets follows CBE label changes Johnson & Johnson and BionPharma made for their branded OTCs containing the ingredient in 2019.
US OTC Decisions In June: Third Tentative Approval For Omeprazole Delayed Release ANDA, More Esomeprazole PPI Final Approvals
FDA told P&L Development, as it had with Aurobindo Pharma and Hetero Drugs, that its ANDA for a generic of Prilosec OTC delayed release is tentatively approved because exclusivity has not expired for Perrigo's first-approved generic of the PPI.
Renewed Political Pressure on Hydroxychloroquine for COVID Highlights Need For Independent US FDA
Bowing to President Trump’s latest push to authorize the anti-malarial drug for COVID-19 could damage the reputation of the agency for the duration of the pandemic and beyond, experts say, arguing it may be the best example yet of why the FDA’s decision making needs to be more clearly delineated from the country’s political leadership.
Need a specific report? 1000+ reports available
Buy Reports